drugset / Trial / NCT06680752
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Timeline
- Start
- 2025-05-20
- Primary completion
- 2028-10
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARD103 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |